clinically benign disease.' Open surgery, involving enucleation of hyperplastic nodules, has been largely replaced by transurethral prostatectomy (TURP) with its lower complication rate. These latter specimens may also decline as other forms of treatment for hyperplasia (for example, stents, drugs, lasers, microwave therapy) prove their efficacy.
In previous years finger guided transrectal or, more rarely, transperineal biopsies were performed on patients with symptoms of prostatism and in whom digital rectal examination (DRE) was suggestive of malignancy or in patients presenting with metastatic disease in whom a primary carcinoma was not clinically apparent. As up to 60% of patients with clinically apparent prostatic carcinoma are known to have metastatic disease at presentation, the value of a malignant diagnosis on biopsy was most commonly to permit palliation by hormonal therapy. Following the success in the USA in detecting prostate confined adenocarcinoma by annual DRE and the possibility of detecting impalpable carcinomas by elevated serum prostate specific antigen (PSA) and transrectal ultrasound (TRUS),2 the frequency of prostatic biopsies has increased in Britain. Fine needle aspiration cytology is an alternative to biopsy, but is not widely practised in Britain and is beyond the scope of this Broadsheet.
In Britain controversy surrounds radical prostatectomy. Attention is drawn to the limited knowledge of the natural history of prostatic cancer, the absence ofvalid randomised studies on surveillance versus treatment (radical prostatectomy and radical radiotherapy) and the inadequacy of current clinical staging systems to distinguish gland confined (usually equated with curable) and locally extensive disease (in which postoperative tumour recurrence is likely). Nevertheless, some surgeons see radical prostatectomy as the only potential cure and more acceptable, as innovation in techniques has reduced the postoperative incidence of incontinence and impotence. The number of centres in which radical surgery is practised is still relatively small, but is increasing.
The dissection of the prostate as a component of radical cystectomy has been described in a previous Broadsheet.3 Needle biopsy Biopsy protocols vary. Some are confined to sampling a palpable or hypoechoic ultrasound lesion, whereas others (especially when an elevated serum PSA is the sole abnormality) extend to quadrant or sextant biopsies. These may include the gland apex and seminal vesicles and are sometimes referred to as "staging biopsies". Screening for prostatic cancer is controversial but pilot studies are being carried out in Britain and the USA.2 The use of biopsy to monitor disease after radical radiotherapy has also become more frequent.
The size of the biopsy specimen is governed by the needle used. The 18 gauge needle provides less than half the amount of tissue as the traditional 14 gauge needle, but is becoming more widely used because of reduced rates of post-biopsy infection and haemorrhage.4 These finer biopsy specimens fragment easily but this can be minimised by transferring the specimen directly from the needle into a cassette. Formol saline is the fixative commonly used, but Bouin's solution gives superior nuclear definition which is valuable in the diagnosis of carcinoma and prostatic intraepithelial neoplasia (PIN). The length of the biopsy is measured (without handling) to ensure that the entire biopsy is represented in subsequent sections. Multiple sections are routinely requested as additional diagnostic confidence is derived from seeing levels of a lesion or, less commonly, a malignant focus may be restricted to a number of sections. A proportion of these specimens will contain unsuspected foci of adenocarcinoma, and controversy surrounds the sampling necessary to detect such tumours and their significance. In a study of 457 TURPs processed in their entirety carcinoma was diagnosed in 14 2%." Three series, each including a minimum of 100 TURPs, compared the results of a variety of restricted and total sampling methods. Carcinoma was diagnosed in 7-8% of TURPs on restricted sampling and 14-19% of those in which all the tissue was processed.'2-l' A further study'5 expressed the results as the probability of detecting different proportions of carcinoma in TURPs according to the percentage processed.
In practice the proportion of TURP fragments invaded by carcinoma fall into two groups, reflecting the classification commonly used in the USA'6: stage Al, carcinoma in up to 5% of the tissue; stage A2, carcinoma in over 5% of the tissue or of high grade (combined Gleason grades 7 to 10). The UICC system is used in Britain and the similar range of stages is Tla (Al) and Tlb (A2)."7 The percentage of involved chips provides similar prognostic information to more detailed and time consuming morphometric analyses of surface area. 18 Thirty two per cent of patients with A2 disease will develop progressive disease in four years.'6 Progression of Al disease becomes apparent on longer follow up-27% at 10 years.'9 Therefore, depending on the physiological age of the patient, some form of radical therapy may be offered in certain centres. Most restricted sampling systems will permit detection of the high volume A2 carcinoma (and the equivalent Tlb disease), but may not detect the Al group or the small subgroup of A2 disease defined as "5% of fragments or less but of high grade".
From the above knowledge of disease course and sampling dependent detection, the following approach is suggested for processing TURPs. The entire specimen from men aged 60 years or less is processed and one section examined from each block, as these patients may expect to live for an average of a further 10 years and even Al disease may progress in this time. As TURPs in this age group are not common, this approach will not add greatly to the laboratory workload. In patients aged over 60 years in centres where radical treatment for A1 disease is practised, the urologists must select an age beyond which they would not consider radical treatment. All TURP tissue from men below this age is processed and examined as above. In patients above the selected age, some form of sampling is applied. If the TURP weighs 12 g or less it is processed in its entirety. In excess of this weight, the system used by the authors is to process a minimum of 12 g, plus 2 g for every 5 g in excess of 12 g. It is important that the urologists are aware that a sampling system is operated so that a degree of corporate responsibility is assumed. Exceptions are obviously made to this protocol ifsurgeons strongly suspect cancer and request examination of further tissue when a benign diagnosis has been made. Also if stage Al carcinoma is found, examination of all the remaining tissue has been recommended to confirm the staging. This is not required in stage A2 disease as the percentage involved is unlikely to decrease with greater sampling. 20 The demonstration of high grade PIN should lead to further sampling because of its high association with concomitant carcinoma. 5 The macroscopic report includes the total weight of the specimen, the weight processed and the number ofcassettes. In those specimens being sampled, any white or yellow fragments (which may prove to be tumour) are Prostatectomy specimens vary widely in shape and size, but hardly ever conform to the diagrammatic inverted cone seen in textbooks with the base at the bladder neck tapering to the apex adjacent to the external sphincter. The gland is best orientated by the knowledge that the seminal vesicles are posterior and superior (sometimes partially embedded in the gland), the posterior surface is flat and the anterior convex. A sound passed through the urethra will frequently show that the anterior aspect of the gland is shorter than the posterior.
The prostate is fixed in formol saline for 24 hours and its weight and dimensions recorded. The entire surface of the specimen is inked, two colours being used to indicate laterality. A third colour is used to paint a line down the centre of the anterior surface to facilitate subsequent orientation and minimise errors. At this stage, the limits are sampled including the vas deferens, bladder neck and urethra. The vasa deferens are identified as short stumps medial to the seminal vesicles. The complete circumference of the bladder neck and urethra are taken as "shave" limits. The distal orifice often seems to retract into the anterior wall of the specimen but is demonstrated by a sound passed through the urethra. Sampling the urethra frequently excavates the prostate. If the specimen is simply held vertically and a slice taken across the distal tissue, this may not include the urethral limit. The entire specimen held vertically is then divided into blocks 5 The blocks are labelled consecutively in ink from the apex to the base and seminal vesicles. Numbers are written at a consistent site and help to indicate to the MLSO both the surface to be cut and the orientation on the slide (fig  2A) . These blocks are then fixed for a further 24 hours in formol saline. A thinner block can then be taken from each numbered surface for routine processing, giving the residual slice the original number of the corresponding processed block so that adjacent tissue can be examined if necessary. Alternatively, the full thickness blocks can be processed providing the processing schedule is modified to take into account the size and texture of the block.
MICROSCOPY
The site and the area occupied by the tumour may be given for each level for clinicians wishing to compare the morphological and ultrasound findings, or the location may be summarised. Some 2B) , and the areas measured using squared paper or by computer aided techniques. The summated areas are multiplied by the interval between the sections (5 mm). The predictive value is greatest when quantitative Gleason grade and volume are combined. In a study of 209 carcinomas 58% of cases with more than 3-2 ml of grades 4 to 5 had nodal metastases, whereas below this volume the frequency was 0.58%.27
Resection margins
Resection margin positivity is most common posteriorly, posterior-laterally and at the urethral limit. The frequency with which tumour is present at these sites relates to its natural distribution in the peripheral zone and at the apex of the gland, unfortunately close to the nerves and striated muscle that the surgeon is trying to preserve to enable the patient to retain potency and continence.
The problems encountered in the interpretation of the relation between tumour and limits of excision are clearly discussed by Epstein.28 Carcinoma in the shave urethral limit is reported as positive by the authors, but in other departments, apical limits are only recorded as positive if carcinoma is seen in striated muscle or, if tumour is seen in prostate but not in striated muscle, it is of high grade or part of the major tumour. Interpretation of the peripheral limits is confused by the term "capsule" which is variable in structure and distribution and is frequently absent. Identification ofthe "capsule" is made more difficult by the desmoplastic response commonly seen around tumours which invade adipose tissue. Therefore, a terminology independent of "capsule" and widely used in America is being adopted. It depends on defining three limits: 1 Contour of the gland at low power which is dictated by muscle outline. Benign acini are virtually always within this limit and beyond it is adipose tissue. However, rare exceptions can occur. 2 The tissue external to the muscle outline, which may be up to 1 cm in width consisting of adipose/fibrous tissue, blood vessels and nerves but may simply be strands of fibrous tissue. 3 The inked resection edge.
Rarely, when the gland has been incised during removal, limits 1 and 2 will be absent.
These definitions allow the tumour to be classified as:
1 Gland confined: within the muscle outline. 2 Specimen confined but outside the gland:
invading beyond the muscle outline but not present at the inked surgical limit. 3 Limit positive disease: tumour present at the inked margin.
In limit positive disease the important feature is the extent of invasion. 46 Increased expression of bcl-2 has been correlated with the progression of prostatic cancer from androgen responsive to androgen independent. 47 This has also been the case for p53 overexpression."
